Pierre Deltenre1,2, Eric Trépo1,3, Naoto Fujiwara4, Nicolas Goossens4,5, Astrid Marot6, Margaux Dubois7, Laurent Spahr5, Jean Henrion8, Christophe Moreno1,3, Yujin Hoshida4. 1. Department of Gastroenterology, Hepatopancreatology, and Digestive Oncology, C.U.B. Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium. 2. Department of Gastroenterology and Hepatology, Clinique St Luc, Bouge, Belgium. 3. Laboratory of Experimental Gastroenterology, Université Libre de Bruxelles, Brussels, Belgium. 4. Division of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA. 5. Division of Gastroenterology and Hepatology, Geneva University Hospital, Geneva, Switzerland. 6. Department of Gastroenterology and Hepatology, CHU UCL Namur, Université Catholique de Louvain, Yvoir, Belgium. 7. Division of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland. 8. Department of Gastroenterology and Hepatology, Hôpital de Jolimont, Haine-Saint-Paul, Belgium.
Abstract
BACKGROUND: The gene-signature-model for end stage liver disease (gs-MELD) score has been shown to be a strong predictor of 6-month survival in severe alcoholic hepatitis (AH). Currently, only a few studies have evaluated the long-term prognosis of patients with severe AH. AIM: To assess the prognostic value of the gs-MELD score at 5 years in patients with severe AH. METHODS: Forty-eight consecutive patients with AH (25 males, median age 52 years [95% IC: 48-56]) were included. RESULTS: The median gs-MELD score was 2.6 (95% CI: 2.2-3.0). According to the gs-MELD score, 22 patients (46%) were considered to have a poor prognosis. During a median follow-up of 29 months (95% CI: 4-43), 19 patients (40%) were abstinent and 24 patients (50%) died. At 5 years, rates of survival were 61% (95% CI: 41-81) and 26% (95% CI: 11-55) in patients with low and high gs-MELD scores (P = .001), and 81% (95% CI: 58-96) and 22% (95% CI: 10-47) in abstainers and in consumers (P < .001) respectively. In multivariable competing risk regression modelling, gs-MELD score (subdistribution hazard ratio: 5.78, 95% CI: 2.17-15.38, P < .001) and recurrent alcohol consumption (subdistribution hazard ratio: 12.18, 95% CI: 3.16-46.95, P < .001) were independently associated with 5-year mortality. CONCLUSIONS: Both gs-MELD score and alcohol consumption drive AH long-term prognosis. The gs-MELD score may guide the development of molecularly targeted therapies in AH.
BACKGROUND: The gene-signature-model for end stage liver disease (gs-MELD) score has been shown to be a strong predictor of 6-month survival in severe alcoholic hepatitis (AH). Currently, only a few studies have evaluated the long-term prognosis of patients with severe AH. AIM: To assess the prognostic value of the gs-MELD score at 5 years in patients with severe AH. METHODS: Forty-eight consecutive patients with AH (25 males, median age 52 years [95% IC: 48-56]) were included. RESULTS: The median gs-MELD score was 2.6 (95% CI: 2.2-3.0). According to the gs-MELD score, 22 patients (46%) were considered to have a poor prognosis. During a median follow-up of 29 months (95% CI: 4-43), 19 patients (40%) were abstinent and 24 patients (50%) died. At 5 years, rates of survival were 61% (95% CI: 41-81) and 26% (95% CI: 11-55) in patients with low and high gs-MELD scores (P = .001), and 81% (95% CI: 58-96) and 22% (95% CI: 10-47) in abstainers and in consumers (P < .001) respectively. In multivariable competing risk regression modelling, gs-MELD score (subdistribution hazard ratio: 5.78, 95% CI: 2.17-15.38, P < .001) and recurrent alcohol consumption (subdistribution hazard ratio: 12.18, 95% CI: 3.16-46.95, P < .001) were independently associated with 5-year mortality. CONCLUSIONS: Both gs-MELD score and alcohol consumption drive AH long-term prognosis. The gs-MELD score may guide the development of molecularly targeted therapies in AH.
Authors: Philippe Mathurin; John O'Grady; Robert L Carithers; Martin Phillips; Alexandre Louvet; Charles L Mendenhall; Marie-José Ramond; Sylvie Naveau; Willis C Maddrey; Timothy R Morgan Journal: Gut Date: 2010-10-12 Impact factor: 23.059
Authors: Yujin Hoshida; Augusto Villanueva; Masahiro Kobayashi; Judit Peix; Derek Y Chiang; Amy Camargo; Supriya Gupta; Jamie Moore; Matthew J Wrobel; Jim Lerner; Michael Reich; Jennifer A Chan; Jonathan N Glickman; Kenji Ikeda; Masaji Hashimoto; Goro Watanabe; Maria G Daidone; Sasan Roayaie; Myron Schwartz; Swan Thung; Helga B Salvesen; Stacey Gabriel; Vincenzo Mazzaferro; Jordi Bruix; Scott L Friedman; Hiromitsu Kumada; Josep M Llovet; Todd R Golub Journal: N Engl J Med Date: 2008-10-15 Impact factor: 91.245
Authors: Christophe Moreno; Pierre Deltenre; Christelle Senterre; Alexandre Louvet; Thierry Gustot; Boris Bastens; Axel Hittelet; Marie-Astrid Piquet; Wim Laleman; Hans Orlent; Luc Lasser; Thomas Sersté; Peter Starkel; Xavier De Koninck; Sergio Negrin Dastis; Jean Delwaide; Isabelle Colle; Chantal de Galocsy; Sven Francque; Philippe Langlet; Virginie Putzeys; Hendrik Reynaert; Delphine Degré; Eric Trépo Journal: Gastroenterology Date: 2016-01-05 Impact factor: 22.682
Authors: Augustin G L Vannier; Vladislav Fomin; Raymond T Chung; Suraj J Patel; Esperance Schaefer; Russell P Goodman; Jay Luther Journal: Gastro Hep Adv Date: 2022-03-30
Authors: Augustin G L Vannier; Jessica E S Shay; Vladislav Fomin; Suraj J Patel; Esperance Schaefer; Russell P Goodman; Jay Luther Journal: JAMA Netw Open Date: 2022-05-02
Authors: Margaux Dubois; Amedeo Sciarra; Eric Trépo; Astrid Marot; Joan Saldarriaga; Christophe Moreno; Christine Sempoux; Pierre Deltenre Journal: United European Gastroenterol J Date: 2020-08-10 Impact factor: 4.623